#	Aladdin ID	Assay Type	Description	Organism	Compounds	Reference	BAO Format	Source
1.	ALA3992284	B	Binding affinity to recombinant full-length N-terminal hexahistidine-tagged c-Myc (353 to 437 residues) bHLH-ZIP domain (unknown origin) expressed in Escherichia coli BL21 DE3 (pLysS) by fluorescence polarization assay	Homo sapiens	27		assay format	Patent Bioactivity Data
2.	ALA3992286	B	Binding affinity to human hexahistidine-tagged Max p21 bHLH-ZIP domain expressed in Escherichia coli M15 (pRep4) at 10 uM by fluorescence polarization assay	Homo sapiens	6		assay format	Patent Bioactivity Data
3.	ALA3992289	B	Binding affinity to recombinant full-length N-terminal hexahistidine-tagged c-Myc (353 to 437 residues) bHLH-ZIP domain (unknown origin) expressed in Escherichia coli BL21 DE3 (pLysS) assessed as changes in shape or intensity of CD spectrum at 5 uM by circular dichroism assay	Homo sapiens	6		assay format	Patent Bioactivity Data
4.	ALA3992290	B	Binding affinity to recombinant full-length N-terminal hexahistidine-tagged c-Myc (353 to 437 residues) bHLH-ZIP domain (unknown origin) expressed in Escherichia coli BL21 DE3 (pLysS) assessed as changes in alpha1H signals of Phe 374 to 375 and Tyr 402 residues at 500 uM by NMR spectroscopy	Homo sapiens	1		assay format	Patent Bioactivity Data
5.	ALA3992292	B	Binding affinity to recombinant full-length N-terminal hexahistidine-tagged c-Myc (353 to 437 residues) bHLH-ZIP domain (unknown origin) expressed in Escherichia coli BL21 DE3 (pLysS) assessed as changes in COSY spectra in alpha1H region at 500 uM by NMR spectroscopy	Homo sapiens	3		assay format	Patent Bioactivity Data
6.	ALA3992293	B	Binding affinity to recombinant full-length N-terminal hexahistidine-tagged c-Myc (353 to 437 residues) bHLH-ZIP domain (unknown origin) expressed in Escherichia coli BL21 DE3 (pLysS) assessed as changes in NOESY spectra at 500 uM by NMR spectroscopy	Homo sapiens	1		assay format	Patent Bioactivity Data
7.	ALA3992294	B	Inhibition of recombinant full-length N-terminal hexahistidine-tagged c-Myc (353 to 437 residues) bHLH-ZIP domain (unknown origin) expressed in Escherichia coli BL21 DE3 (pLysS)/human hexahistidine-tagged Max p21 expressed in Escherichia coli M15 (pRep4) assessed as disruption of E-Box DNA binding preincubated for 30 mins with c-Myc followed by Max p21 and E-box element addition measured after 15 mins by electrophoretic mobility shift assay	Homo sapiens	6		assay format	Patent Bioactivity Data
8.	ALA3992296	F	Cytotoxicity against human HL60 cells expressing c-Myc assessed as growth inhibition after 4 to 5 days by MTT assay	Homo sapiens	16		cell-based format	Patent Bioactivity Data
9.	ALA3992297	F	Cytotoxicity against human Daudi Burkitt lymphoma cells expressing c-Myc assessed as growth inhibition after 4 to 5 days by MTT assay	Homo sapiens	15		cell-based format	Patent Bioactivity Data
10.	ALA3992298	A	Cytotoxicity against non-transformed rat TGR1 assessed as growth inhibition after 4 to 5 days by MTT assay	Rattus norvegicus	11		cell-based format	Patent Bioactivity Data
11.	ALA3992299	A	Cytotoxicity against c-Myc null rat TGR1 reconstituted with HMGA1b or MT-MC1 assessed as growth inhibition after 4 to 5 days by MTT assay	Rattus norvegicus	11		cell-based format	Patent Bioactivity Data